Background We studied the effect on tumour response to neoadjuvant therapy of the substitution
of lapatinib for trastuzumab in combination with weekly paclitaxel after doxorubicin plus …

PURPOSE: Uncertainty about the relative worth of doxorubicin/cyclophosphamide (AC) and
cyclophosphamide/methotrexate/fluorouracil (CMF), as well as doubt about the propriety of …

Purpose: Paclitaxel is an active drug for the treatment of breast cancer; however, the appropriate
duration of administration is unknown. We assessed and compared the response rate, …

Background. Recognition of a biologic marker in colorectal cancer tissue that correlates with
recurrence and poor survival would offer a rationale for planning aggressive adjuvant …

LBA506 Background: The purposes of this trial are to determine the effect of substituting
lapatinib (L) for trastuzumab (T) in combination with weekly paclitaxel (WP) following AC as well …

During progression from benign nevus to vertical growth phase melanoma, melanocytes
acquire the ability to invade into the dermis. This process requires rupture of the basal lamina …

THE metabolic effects of malabsorption due to loss of extensive lengths of small bowel in
humans has been studied haphazardly. The small bowel was usually removed as an …

501 Background: The primary aim of this randomized trial of neoadjuvant therapy in operable,
HER2-positive breast cancer (BC) was to determine the effect on pathologic complete …

Background The primary aim of this randomized neoadjuvant trial in operable, HER2-positive
breast cancer, was to determine the efficacy on pathologic complete response (pCR) of …

Integrin alpha v beta 3 is a marker of progression in malignant melanoma. Previously we
reported that human melanoma cells derived from regional lymph node metastases had …